ORIC Pharmaceuticals Inc (ORIC)
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
📈 **POSITIVE** • Low confidence analysis (53%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (80%) **Content type:** Clinical